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Abstract
Background: Malignant transformation describes the phenomenon in which a somatic component of a germ cell
teratoma undergoes malignant differentiation. A variety of different types of sarcoma and carcinoma, all non-germ
cell, have been described as a result of malignant transformation.
Case presentation: A 33-year-old man presented with a left testicular mass and elevated tumour markers. Staging
investigations revealed retroperitoneal lymphadenopathy with obstruction of the left ureter and distant metastases.
Histopathology from the left radical orchiectomy showed a mixed germ cell tumour (Stage III, poor prognosis). The
ureter was stented and four cycles of cisplatin, etoposide and bleomycin chemotherapy administered. After initial
remission, the patient recurred four years later with a large retroperitoneal mass involving the renal vessels and the
left ureter. Left retroperitoneal lymph node dissection with en-bloc resection of the left kidney was performed.
Histopathology revealed a germ cell tumour metastasis consisting mainly of mature teratoma. Additionally, within
the teratoma a papillary renal cell carcinoma was found. The diagnosis was supported by immunohistochemistry
showing positivity for AMACR, CD10 and focal expression of RCC and CK7. There was no radiological or histo-
pathological evidence of a primary renal cell cancer.
Conclusions: To the best of our knowledge, malignant transformation into a papillary renal cell carcinoma has not
been reported in a testicular germ cell tumour metastasis following platinum-based chemotherapy. This histological
diagnosis might have implications for potential future therapies. In the case of disease recurrence, renal cell cancer
as origin of the recurrent tumour has to be excluded because renal cell carcinoma metastases would not respond
well to the classical germ cell tumour chemotherapy regimens.
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Background
Teratoma is a tumour of embryonic origin and belongs to
the group of non-seminomatous germ cell tumours
(GCT) [1]. Primarily, it occurs most often in the testis or
ovary but may also appear in other body sites such as the
central nervous system, mediastinum or retroperitoneum
[2]. Non-seminomatous GCT can be pure teratoma but
mixed forms with other non-seminomatous histologies
occur more frequently. However, teratoma is often the
only component that remains histologically detectable in
residual lesions after platinum-based chemotherapy for
metastatic mixed non-seminomatous GCT.
Teratoma typically contains different types of tissue
derived from all three germinal layers, the endoderm,
mesoderm and ectoderm. It can be of cystic or solid
appearance and depending on the degree of differentiation
seen it is classified as mature or immature teratoma [1].
The immature form is characterised by somatic differen-
tiated cells in an early ‘embryonal’ stage. A mature teratoma
consists of fully differentiated somatic tissues such as carti-
lage, epidermis, nerve tissue, glands or even complex
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organs. Mature renal tissue has rarely been reported
to be a part of mature teratoma [3].
Somatic malignant transformation (MT) refers to ma-
lignant de-differentiation of teratoma components [2]. It
is a well-described phenomenon, characterized by diffe-
rentiation of pluripotent teratoma cells into somatic
tumour cells [2,4-7]. Usually MT occurs in adult patients
with metastatic GCT disease and can arise either in the
primary or metastatic site of the tumour [6]. Sarcoma is
the most frequently described malignant histology but a
variety of other tumour entities including enteric adeno-
carcinoma, primitive neuroectodermal tumour (PNET)
and leukaemia have also been found [2,4-6]. To the best
of our knowledge, MT into papillary renal cell cancer
has never been reported in a testicular GCT metastasis
following platinum-based chemotherapy.
Case presentation
A 33-year-old man presented with a left-sided, painless
scrotal mass suspicious for testicular cancer. Scrotal ultra-
sound showed a 3 cm mass of heterogeneous echogenicity
in the left testicle with irregular, poorly defined
borders. Serum tumour markers were elevated with
an alpha-fetoprotein (AFP) of 28135 μg/l, beta-human
chorionic gonadotropin (ß-HCG) of 19700 U/l and
lactate dehydrogenase (LDH) of 4421 U/l. Staging thoraco-
abdominal computed tomography (CT) showed bulky
retroperitoneal lymphadenopathy, left hydronephrosis,
metastases to both liver and lung, as well as mediastinal
and supraclavicular lymphadenopathy.
The patient underwent left inguinal orchiectomy and
routine biopsy of the contra-lateral testis in a secondary
referral centre. A double-J stent was inserted into the
left ureter.
Histo-pathological examination of the left testis
revealed a mixed GCT consisting of two-thirds classical
seminoma and one-third non-seminomatous tumour
with embryonal carcinoma and yolk sac tumour compo-
nents. In the adjacent parenchyma intra-tubular germ
cell neoplasia was found. The right testis biopsy showed
normal testicular tissue without intra-tubular germ cell
neoplasia. The tumour stage was determined to be pT1
cN3 cM1b S3 (TNM; [7]) and clinical stage IIIC poor
prognosis group (Lugano classification; [8]).
Subsequently, the patient was discharged to a commu-
nity oncologist and treated with four cycles of cisplatin,
etoposide and bleomycin chemotherapy. Five months
after completing chemotherapy all serum tumour
markers normalised. Regular follow-up thoraco-
abdominal CTs showed residual retroperitoneal and
supra-clavicular lymphadenopathy, along with sub-
centimetre pulmonary and liver masses. As these
post-chemotherapy lesions were small and did not
show interval growth, surgical resection was not
performed. Four and a half years after orchiectomy
the patient was referred to our academic tertiary
referral centre with a newly enlarging retroperitoneal
mass. Fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) had been performed at the com-
munity and this demonstrated a partially FDG-avid
retroperitoneal mass infiltrating the left renal vessels,
left ureter and abdominal aorta (Figure 1a-c).
Tumour markers remained normal. The hepatic,
pulmonary, mediastinal and supra-clavicular lesions
were unchanged. Both kidneys appeared normal on
abdominal CT and FDG-PET.
Left retroperitoneal lymphadenectomy with en-bloc
resection of the left kidney and the infrarenal aorta was
performed. An aorto-bi-iliacal graft was inserted.
Figure 1 Pre-operative positron emission tomography showing a large retroperitoneal mass with a centrally located metabolic activity
of 2.4 cm in diameter (a). Computed tomography (CT) with the large retroperitoneal mass and involvement of the renal vessels (b). A kidney
tumour was detectable neither in the right nor in the left hydronephrotic kidney (c).
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Histopathological findings
Histology of the en-bloc resected specimen revealed a retro-
peritoneal GCT metastasis with a maximum diameter of
12 cm. The metastasis consisted of mature cystic teratoma
containing peripheral nerves, cartilage and respiratory,
squamous and pigmented epithelium (Figure 2a and b).
Within the teratoma, a 2.5 cm lesion with the typical
appearance of a papillary renal cell carcinoma was
found. Areas of papillary and tubular histoarchitecture
were seen (Figure 3a). The cell nuclei appeared to be
pleomorphic containing fine-granular chromatin. The
cytoplasm of these cells was eosinophilic (Figure 3b).
Immunohistochemistry showed strong positivity for
alpha-methylacyl-CoA racemase (AMACR, Figure 3c),
CD 10 (not shown), focal expression of renal cell carcinoma
antigen (RCC; Figure 3d) and cytokeratin 7 (CK 7;
not shown). Vimentin and AFP were negative (not shown).
Histologically, no renal cell cancer was found in the
removed left kidney.
Follow-up
No additional chemotherapy was administered after
surgery. Currently, 2 years after retroperitoneal lymphade-
nectomy, the patient remains progression-free with stable
disease showing no further tumour growth, metabolic
PET-activity or tumour marker elevation.
Discussion
Somatic MT develops in 3-6% of chemotherapy-naïve
patients with metastatic GCT containing teratomous
components [4,9]. After platinum-based chemotherapy the
incidence of MT increases up to 14% [4]. Histologically,
various types of sarcoma and carcinoma have been
identified in GCT with MT. The most commonly
MTs reported are rhabdomyosarcoma, PNET and
adenocarcinoma. Leiomyosarcoma, liposarcoma, chondro-
sarcoma, Non-Hodgkin’s lymphoma and leukaemia are
found less frequently [2,3,6]. Renal tumour differentiation
is rare. Nephroblastoma (Wilms tumour) have been
described [6] and there is a single report of MT into
papillary renal cell carcinoma in a primary retroperitoneal
and chemotherapy-naïve GCT [10]. To the best of our
knowledge, MT into papillary renal cell cancer within
a testicular GCT metastasis following platinum-based
chemotherapy has not been previously documented.
It is highly unlikely that the papillary renal cell cancer
found was a metastasis originating from the kidneys. We
believe the papillary renal cell carcinoma resulted from
MT of the teratoma for several reasons. Firstly, the
lesion was located within the teratoma. Secondly, both
kidneys had normal appearance on multiple abdominal
CTs and FDG-PET. Finally, there was no histological
evidence of renal cell cancer in the left kidney that was
removed en bloc. There was also no family history of
papillary renal cell cancer. In cases with more clinical
ambiguity, fluorescence in situ hybridisation (FISH)
analysis for 12p amplification can be used to confirm the
germ-cell origin of somatic-type tumours of uncertain
histogenesis [11].
The characteristic morphology and the immunohisto-
chemical profile confirmed the diagnosis of papillary renal
cell cancer. Papillary renal cell cancer is differentiated from
other subtypes of renal cell cancer by using CK7 and
AMACR immunohistochemical markers [12]. Most papil-
lary renal cell carcinomas are positive for CK7, whereas
clear cell renal cell cancer shows either negative or only a
focal or expression pattern [13]. A panel of immunohisto-
chemical markers, including CD10, RCC, and vimentin, has
been proposed for the identification of renal origin of a
metastatic tumour [12,14]. Identification of the most
common chromosomal aberrations in papillary renal cell
cancer (trisomy of chromosome 7 and 17 as well as loss of
Y chromosome [15]) were not necessary in our case due to
convincing histological and immunohistochemical features.
The role of FDG-PET in evaluating residual masses
after chemotherapy differs between seminomatous and
non-seminomatous GCTs [16]. FDG-PET can discrimi-
nate between viable tumour and fibrosis or necrosis in
post-chemotherapy residuals of seminomatous GCT
[17,18]. Therefore, FDG-PET is recommended to decide
Figure 2 Hematoxylin and eosin (HE) staining of the mature teratoma containing pigmented epithelium (arrows a), cartilage
(arrowhead a), peripheral nerves (asterisk a) as well as squamous epithelium (arrows b). Magnification: 100x.
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whether surveillance or surgical therapy is the treatment
of choice in patients with residuals > 3 cm [19]. However,
in the setting of a non-seminoma post-chemotherapy
mass FDG-PET is not recommended [19]. Although it
can detect viable tumour in residual masses, it cannot
discriminate mature teratoma from fibrosis or necrosis
[20]. Therefore FDG-PET is not helpful to decide if
surgical therapy is necessary or not in these patients.
In our case of non-seminomatous GCT, FDG-PET was
performed contradictory to standard guidelines prior
referral to our centre. Histo-pathological examination
revealed that the FDG-avid lesion within the retroperi-
toneal teratoma represented the papillary renal cell
cancer. It has been reported that FDG-PET may have a
role in detecting metastasis of renal cancer. However
this is usually in the setting of clear cell rather than
papillary carcinoma [21].
Due to the wide spectrum and unpredictability of
tumour types that occur in MT, the utility of FDG-PET
in the setting of MT remains unknown and requires
further investigation. Tissue diagnosis is still the gold
standard in determining presence of viable malignancy and
discriminating between GCT and other types of tumours.
The occurrence of MT is known to worsen the prognosis
of GCT, particularly in metastatic disease [6,22-24]. One
reason for this is that many of the tumours found after
MT are highly aggressive (i.e. sarcoma, PNET) [25,26]. If
MT remains undetected, a conventional platinum-based
chemotherapy approach may fail in treating the new
tumour type developed. This may additionally delay
diagnosis of MT and lead to worse outcome [27,28].
Complete surgical resection, if technically possible,
should remain the gold standard of therapy as it will
achieve the most reliable histopathologic diagnosis, and
has been shown to improve the prognosis of patients with
MT in metastatic GCT [2,3,6,27]. If MT is found, histo-
logical evaluation is mandatory for all synchronously or
metachronously detected metastases. In advanced cases
with documented spread of the transformed histologic
subtype, systemic therapies targeted to the identified
tumour type should be considered [6,9,27,29].
Conclusions
To the best of our knowledge, MT into papillary
renal cell carcinoma has not been reported in the
setting of metastatic testicular germ cell tumour
following platinum-based chemotherapy. Our case
highlights the importance of complete surgical resec-
tion and histological diagnosis of residual masses after
chemotherapy of metastatic non-seminomatous GCTs
to allow tailoring of potential subsequent therapies to
the transformed tumour type.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Series Editor of this journal
Figure 3 Overview (a) and detailed view (b) of the papillary renal cell carcinoma within the teratoma. The HE staining shows the typical
papillary histoarchitecture with pleomorphic nuclei, fine-granular chromatin and eosinophilic cytoplasm (a, b). Immunohistochemistry (c, d) with
positive immunoreactivity for alpha-methylacyl-CoA racemase (AMACR) (c) and focal positivity for renal cell carcinoma antigen (RCC) (d).
Magnification: 100x (a,c,d), 400x (b).
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